CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Eurofins-Cerep SA Company Snapshot
Eurofins-Cerep SA operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Eurofins-Cerep SA with three other companies in this sector in France: Cellectis SA (2018 sales of 18.19 million Euro [US$20.41 million] of which 98% was Therapeutics), Oncodesign Sa (20.09 million Euro [US$22.54 million] ), and Ose Immunotherapeutics SA (24.46 million Euro [US$27.45 million] ).

Sales Analysis. During the year ended December of 2018, sales at Eurofins-Cerep SA were 25.45 million Euro (US$28.57 million). This is an increase of 4.3% versus 2017, when the company's sales were 24.41 million Euro. This was the fourth straight year of sales growth at Eurofins-Cerep SA.
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Eurofins-Cerep SA
  Stock Performance Chart for Eurofins-Cerep SA
 
  Stock Data: Recent Stock Performance:
  Current Price (7/18/2019): 5,900.00
(Figures in Euro)
1 Week n/a   13 Weeks -16.9%  
4 Weeks n/a   52 Weeks -5.6%  
 
Eurofins-Cerep SA Key Data:
  Ticker: ALECR Country: France
  Exchanges: PAR Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2018 Sales 25,453,287
(Year Ending Jan 2019).
Employees: 178
  Currency: Euro Market Cap: 29,759,600
  Fiscal Yr Ends: December Shares Outstanding: 5,044
  Share Type: Actions Ordinaires Closely Held Shares: 4,831
 
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.